Results 191 to 200 of about 46,556 (258)

WWOX maintains epidermal identity and suppresses EMT to prevent aggressive cutaneous squamous cell carcinoma. [PDF]

Proc Natl Acad Sci U S A
Bidany-Mizrahi T, Maroun K, Mancini M, Hidmi O, Ansari I, Monin J, Keidar Haran T, Maly A, Melino G, Candi E, Aqeilan RI.   +10 more
europepmc   +1 more source

Targeting RuvBL1 disrupts mitochondrial metabolism and structure in hepatocellular carcinoma. [PDF]

JHEP Rep
Mello T, Simeone I, Guida A, Papini D, Begnozzi F, Santi A, Guasti D, Nardini P, Polvani S, Lulli M, Bereshchenko O, Ceni E, Curto A, Pinton P, Bonora M, Galli A.   +15 more
europepmc   +1 more source

Combination of PARPi and topoisomerase I inhibitors is highly effective in olaparib-resistant ovarian cancer. [PDF]

Exp Hematol Oncol
Chiappa M, Villa V, Sias F, Grasselli C, Sala L, Canesi S, Marabese M, Mason S, Dibitetto D, Fruscio R, Damia G.   +10 more
europepmc   +1 more source

The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer. [PDF]

Cancer Discov
Avolio M, Leto SM, Sassi F, Lupo B, Grassi E, Catalano I, Zanella ER, Vurchio V, Cottino F, Tsantoulis PK, Lazzari L, Luraghi P, Ferri M, Galimi F, Berrino E, Bellomo SE, Viviani M, Sogari A, Mauri G, Tosi F, Cruciani F, Sartore-Bianchi A, Siena S, Borghi F, Torri V, Élez E, Tabernero J, Nieva M, Montagut C, Tarazona N, Cervantes A, Tejpar S, Bardelli A, Marchiò C, Marsoni S, Bertotti A, Trusolino L.   +36 more
europepmc   +1 more source

Terapias personalizadas no cancro

O presente trabalho explora a importância e os avanços das terapias personalizadas no tratamento do cancro, destacando o impacto da epigenética. As terapias personalizadas representam uma abordagem inovadora que permite adaptar tratamentos específicos para cada doente com base no seu perfil genético e epigenético, em vez de seguir as tradicionais ...
openaire   +1 more source

Maladaptive somatic gene rescue as predisposition to JAK2 molecular abnormalities? Insights from an Israeli family. [PDF]

Ann Hematol
Borsani O, Gurnari C, Pietra D, Rumi E.
europepmc   +1 more source

Low Rates of Discontinuation Unrelated to Disease Progression with Trastuzumab Deruxtecan in Metastatic Breast Cancer: A Real-World Study. [PDF]

Cancers (Basel)
Licata L, Patanè F, Guarino A, Galbardi B, Battaglia A, Mariani M, Zanibelli C, Notini G, Naldini MM, Bosi C, Chiavassa A, Piras M, Persano I, Rognone A, Sica L, Zambelli S, Zucchinelli P, Viale G, Bianchini G.   +18 more
europepmc   +1 more source

Multifunctional-engineered NK cells overcome tumor immunosuppression by combining PD-L1 and HLA-E targeting and endogenous IL15 production. [PDF]

Signal Transduct Target Ther
Fiore PF, Forcelloni S, Moretta L, Assenza MR, Orecchia P, Bilotta MT, Machwirth M, Shpati T, Sanvi LW, Haas D, Vitozzi S, Giansanti M, Nazio F, Tumino N, Caruana I, Vacca P.   +15 more
europepmc   +1 more source

Unusual Disease-Progression in Two Siblings With Xeroderma Pigmentosum Group G. [PDF]

Clin Genet
Botta E, Fawcett H, Orioli D, Fassihi H, Lehmann AR.   +4 more
europepmc   +1 more source

Age-associated B cells and double-negative B cells: two sides of the same coin? The answer depends on the context. [PDF]

Front Aging
Lamprinou M, Sachinidis A, Dimitroulas T.   +2 more
europepmc   +1 more source